New data presented in DDW 2022 show nearly double risk of loss of calm in ulcerative colitis patients who developed tissue inflammation at core biopsy.

Durham, North CarolinaAnd May 22 2022 /PRNewswire/ — More than a third (36.6%) of ulcerative colitis (UC) patients who previously responded to advanced treatments experienced a loss of remission (LOR) in symptom control, often within a year, new data shows. Analysis from the large TARGET-IBD array from Target RWE, Inflammation in indicator biopsy predicts loss … Read more